Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized non-comparative trial of bevacizumab and fotemustine in recurrent glioblastoma
2011-001363-46Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) comparing Bevacizumab with Bevacizumab + fotemustine (2 arms). Primary endpoint: 6-month overall survival. Started Dec 2011; status: completed.
02
Drugs
bevacizumabfotemustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2011-001363-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001363-46.